ViroLogic plans further PhenoSense tests:
This article was originally published in Clinica
ViroLogic, which manufactures the PhenoSense HIV drug resistance test, plans to commercialise a PhenoSense assay for entry inhibitors, a new class of anti-HIV drug, by the end of this year. The company says that research has shown that susceptibility to entry inhibitors varies widely among patients who have not yet been exposed to the drugs. ViroLogic, based in South San Francisco, California, is also planning to make a PhenoSense assay for viral fitness (ability to replicate) available for research use by the end of the year, and for clinical use in the first half of 2002.
You may also be interested in...
Pharma manufacturing is operating well below normal levels in India, disrupted by labor absenteeism and supply chain issues amid the ongoing lock-down in the country, though the government is actively engaged in addressing bottlenecks. A speedy recovery is vital not just for domestic supplies.
Moderna is pursuing a single-antigen strategy even though some of its mRNA vaccines have included multiple antigens; the SARS-CoV-2 spike protein likely provides the best antigen for developing immunity against the virus.
Latest warnings also include second and third businesses in US cannabidiol and hemp sector found making unlawful claims for treating and preventing COVID-19. Four of five firms warned apparently responded by removing violative claims from websites and social media posts.